Scientific Publications | SILLAJEN

Scientific Publications

Targeting, Attacking, and Eradicating Cancers®

Scientific Publications

16 cases in total ˙ 1/2 Page

Poster
Preclinical
Clinical

Safety and efficacy of BAL0891 as monotherapy and in combination with paclitaxel in a phase I study of advanced solid tumors

ESMO2026 Poster

NO 16
Dual TTK/PLK1 Inhibition Combined with G-CSF Treatment Synergistically Suppresses Metastatic Progression in Triple-Negative Breast Cancer

AACR 2026 Poster

NO 15
Optimizing Immunomodulation of BAL0891, a TTK/PLK1 Dual Inhibitor, to Enhance Synergy with Immune Checkpoint Blockade Using a Biomimetic Tumor Microenvironment Platform and Pharmacometric Modeling

SITC 2025 Poster

NO 14
A Phase 1 study of mitotic checkpoint inhibitor BAL0891 in combination with Tislelizumab (anti-PD-1 antibody) in patients with advanced soild tumors

SITC 2025 Poster

NO 13
Evaluation of the Antitumor Effects of a Dual TTK/PLK1 Inhibitor in Patient-Derived Gastric Cancer Organoids from Malignant Fluids

AOS 2025 Poster

NO 12
TTK/PLK1 Dual Antagonist BAL0891 Synergizes with Pembrolizumab in a Vascularized 3D Tumor Microenvironment Model

AACR 2025 Poster

NO 11
Profiling Patient Response to TTK/PLK1 Dual Antagonist BAL0891 Using 3D Patient-derived Organoid Model in a Microphysiological System

AACR 2025 Poster

NO 10
BAL0891 as a dual kinase inhibitor inducing anti-tumor immunity: A promising partner for immume checkpoint inhibitors

AACR 2025 Poster

NO 9
PB192 Spatial Analysis of Tumor-infiltrating Lymphocytes in mRCC Patients Treated with Pexa-Vec (Thymidine Kinase-Deactivated Vaccinia Virus plus GM-CSF) and cemiplimab (REGN2810; Anti-PD-1)

EORTC-NCI-AACR 2024 Poster

NO 8
Pexa-Vec and Cemiplimab (Libtayo®) Combination Therapy in Metastatic or Unresectable RCC: Results from SillaJen REN026 Clinical Study

ESMO 2023 Poster

NO 7